CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.5.1 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2027 ($Million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 High competition and fragmented market moderates the power of the suppliers
3.3.2 Scattered and large number of buyers moderates their bargaining power
3.3.3 High capital investment moderates the threat of new entrants
3.3.4 High intensity of rivalry
3.3.5 Unavailability of substitutes lowers the threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
3.5.1 Drivers
3.5.1.1 Growing incidences of congestive heart failures
3.5.1.2 Technological advancements in CHF treatment devices
3.5.1.3 Increasing patient awareness
3.5.1.4 Presence of high-unmet medical needs
3.5.2 Restraints
3.5.2.1 Limited insurance coverage and high cost of the CHF treatment devices
3.5.2.2 unfavorable preference to pharmaceutical interventions (drugs) over CHF treatment devices
3.5.3 Opportunities
3.5.3.1 Lucrative opportunities in emerging economies
3.5.3.2 Development of new MRI-labeled devices
CHAPTER 4 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCT
4.1 Pacemakers
4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
4.1.4 Implantable Pacemakers
4.1.4.1 Market size and forecast
4.1.5 External Pacemakers
4.1.5.1 Market size and forecast
4.2 Cardiac resynchronization therapy (CRT)
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 CRT-P (CRT with pacemaker function)
4.2.4.1 Market size and forecasts
4.2.5 CRT-D (CRT with pacemaker and ICD function)
4.2.5.1 Market size and forecasts
4.3 Implantable cardioverter defibrillators (ICDs)
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.2.1 Market size and forecast
4.3.3 Transvenous implantable cardioverter defibrillator (T-ICDs)
4.3.3.1 Market size and forecasts
4.3.4 Subcutaneous implantable cardioverter defibrillator (S-ICDs)
4.3.4.1 Market size and forecasts
4.4 Ventricular Assist Devices (VADs)
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 Left Ventricular assist device (LVAD)
4.4.4.1 Market size and forecasts
4.4.5 Right ventricular assist device (RVAD)
4.4.5.1 Market size and forecasts
4.4.6 Biventricular Assist Device (BIVAD)
4.4.6.1 Market size and forecasts
CHAPTER 5 WORLD CHF TREATMENT DEVICES MARKET, BY GEOGRAPHY, 2015-2022
5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 U.S.
5.2.4.1 Market size and forecast
5.2.5 Canada
5.2.5.1 Market size and forecast
5.2.6 Mexico
5.2.6.1 Market size and forecast
5.3 Europe
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.3.4 Germany
5.3.4.1 Market size and forecast
5.3.5 France
5.3.5.1 Market size and forecast
5.3.6 U.K.
5.3.6.1 Market size and forecast
5.3.7 Rest of Europe
5.3.7.1 Market size and forecast
5.4 Asia-Pacific
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 India
5.4.4.1 Market size and forecast
5.4.5 China
5.4.5.1 Market size and forecast
5.4.6 Japan
5.4.6.1 Market size and forecast
5.4.7 Rest of Asia-Pacific
5.4.7.1 Market size and forecast
5.5 LAMEA
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.5.4 Latin America
5.5.4.1 Market size and forecast
5.5.5 Middle East
5.5.5.1 Market size and forecast
5.5.6 Africa
5.5.6.1 Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1 Abiomed, Inc.
6.1.1 Company overview
6.1.2 Operating business segments
6.1.3 Business performance
6.1.4 Key strategic moves & developments
6.1.5 SWOT analysis
6.2 Berlin Heart GmbH
6.2.1 Company overview
6.2.2 Operating business segments
6.2.3 Key strategic move & development
6.2.4 SWOT analysis
6.3 Biotronik SE & Co. KG
6.3.1 Company overview
6.3.2 Operating business segments
6.3.3 Key strategic moves & developments
6.3.4 SWOT analysis
6.4 Boston Scientific Corporation
6.4.1 Company overview
6.4.2 Operating business segments
6.4.3 Business performance
6.4.4 Key strategic moves & developments
6.4.5 SWOT analysis
6.5 HeartWare International, Inc.
6.5.1 Company overview
6.5.2 Operating business segments
6.5.3 Business performance
6.5.4 Key strategic moves & developments
6.5.5 SWOT analysis
6.6 Jarvik Heart, Inc.
6.6.1 Company overview
6.6.2 Operating business segments
6.6.3 Key strategic moves & developments
6.6.4 SWOT analysis
6.7 LivaNova PLC
6.7.1 Company overview
6.7.2 Operating business segments
6.7.3 Business performance
6.7.4 Key strategic moves & developments
6.7.5 SWOT analysis
6.8 Medtronic plc
6.8.1 Company overview
6.8.2 Operating business segments
6.8.3 Business performance
6.8.4 Key strategic moves & developments
6.8.5 SWOT analysis
6.9 ReliantHeart, Inc.
6.9.1 Company overview
6.9.2 Operating business segments
6.9.3 Key strategic moves & developments
6.9.4 SWOT analysis
6.10 St. Jude Medical, Inc.
6.10.1 Company overview
6.10.2 Operating business segments
6.10.3 Business performance
6.10.4 Key strategic moves & developments
6.10.5 SWOT analysis
List of Figures